title: Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia.
abstract: Allogeneic transplantation is successful in a minority of patients with primary refractory acute leukemia (PRAL). An HLA-matched sibling donor (MSD) is available only in 30-40% of the patients, whereas a partially mismatched related donor (PMRD) is available for most. We compared the outcome of 24 MSD (median age 24 years) and 19 PMRD (median age 34 years; P = 0.04) allograft recipients with PRAL. All MSD patients received non-T cell-depleted marrow whereas all PMRD patients received partially T cell-depleted marrow. All evaluable PMRD patients and 90% of the evaluable MSD patients attained CR. Six patients in each group with recurrent/persistent disease died. Ten PMRD (3-year probability 70%) and 14 MSD (3-year probability 63%) patients died of treatment-related causes. At the last follow-up, three PMRD (18-50 months; 3-year probability 14%) and four MSD (20-166 months; 3-year probability 20%) patients were alive and well. We conclude that allogeneic transplantation is a viable therapeutic option for PRAL. PMRD transplantation is a reasonable alternative in patients with no MSD, and results in similar outcome. In terms of identifying a donor and harvesting cells, a PMRD transplant is significantly quicker than an unrelated donor transplant - a point of great practical importance in the setting of failed induction chemotherapy where time is of the essence.
authors.affiliation: Royal Marsden Hospital, Surrey, UK.
authors.forename: S
authors.initials: S
authors.lastname: Singhal
authors.forename: R
authors.initials: R
authors.lastname: Powles
authors.forename: P J
authors.initials: PJ
authors.lastname: Henslee-Downey
authors.forename: K Y
authors.initials: KY
authors.lastname: Chiang
authors.forename: J
authors.initials: J
authors.lastname: Treleaven
authors.forename: K
authors.initials: K
authors.lastname: Godder
authors.forename: S
authors.initials: S
authors.lastname: Kulkarni
authors.forename: F
authors.initials: F
authors.lastname: van Rhee
authors.forename: B
authors.initials: B
authors.lastname: Sirohi
authors.forename: C R
authors.initials: CR
authors.lastname: Pinkerton
authors.forename: S
authors.initials: S
authors.lastname: Meller
authors.forename: J
authors.initials: J
authors.lastname: Mehta
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D007938:Leukemia / Q000276:immunology* / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009679:Nuclear Family; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy; D012189:Retrospective Studies; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens